Back

StatPearls, LLC

  • Hemangioma
  • Hemangiosarcoma
  • Neoplasm Metastasis
  • Prognosis

Endovascular Papillary Angioendothelioma

Endovascular papillary angioendothelioma (EPA), also known as Dabska tumor (DT) and papillary intralymphatic angioendothelioma (PILA), represents a borderline entity between hemangioma and angiosarcoma. DT has an overall favorable prognosis; however, there is potential for local recurrence and low-grade metastasis. This activity reviews the evaluation, treatment, and prognosis of endovascular papillary angioendothelioma and highlights the role of the interprofessional team in the care of patients with this condition.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABS — Accredited CMEUp to 1 pointABOS — Accredited CMEUp to 1 pointABPATH — Lifelong LearningUp to 1 pointABTS — Accredited CMEUp to 1 pointABIM — Medical KnowledgeUp to 1 pointABS — Self-AssessmentUp to 1 pointABP — Lifelong Learning and Self-AssessmentUp to 1 pointABTS — Self-AssessmentUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 6 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left